1. Peroxisome Proliferator-Activated Receptor Gamma (PPARG) status defines the luminal lineage in molecular profiles of advanced urothelial cancers (UC). (October 2022) Authors: Motley, W.; Islam, S.; Eagle, K.; Bell, J.; Sims, R.; Bowden, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models. (October 2022) Authors: Mertz, J.; Stuckey, J.; Wilson, J.; Motley, W.; DeLaBarre, B.; Audia, J.; Sims, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗